Compare · HOOK vs HZNP
HOOK vs HZNP
Side-by-side comparison of HOOKIPA Pharma Inc. (HOOK) and Horizon Therapeutics Public Limited Company (HZNP): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both HOOK and HZNP operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- HZNP is the larger of the two at $20.72B, about 504.8x HOOK ($41.0M).
- HZNP has more recent analyst coverage (14 ratings vs 11 for HOOK).
- Company
- HOOKIPA Pharma Inc.
- Horizon Therapeutics Public Limited Company
- Price
- $0.87-3.61%
- $116.30+0.03%
- Market cap
- $41.0M
- $20.72B
- 1M return
- +0.00%
- -
- 1Y return
- -8.41%
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2019
- 2011
- News (4w)
- 0
- 0
- Recent ratings
- 11
- 14
HOOKIPA Pharma Inc.
HOOKIPA Pharma Inc., a clinical stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase II clinical trial in patients awaiting kidney transplantation from cytomegalovirus-positive donors. Its lead oncology product candidates are HB-201 and HB-202 that are in Phase I/II clinical trial for the treatment of human papillomavirus 16-positive cancers. The company has a collaboration with Gilead Sciences, Inc. to develop infectious disease product candidates intended to support functional cures for chronic Hepatitis B virus and human immunodeficiency virus infections. HOOKIPA Pharma Inc. was incorporated in 2011 and is headquartered in New York, New York.
Horizon Therapeutics Public Limited Company
Horizon Therapeutics Public Limited Company, a biotechnology company, focuses on the discovery, development, and commercialization of medicines that address critical needs for people impacted by rare, autoimmune, and severe inflammatory diseases. The company operates in two segments, Orphan and Inflammation. Its portfolio comprises 12 medicines in the areas of rare diseases, gout, ophthalmology, and inflammation. It markets TEPEZZA (teprotumumab-trbw) for intravenous infusion; KRYSTEXXA (pegloticase injection) for intravenous infusion; RAVICTI (glycerol phenylbutyrate) oral liquid; PROCYSBI (cysteamine bitartrate) delayed-release capsules and granules for oral use; ACTIMMUNE (interferon gamma-1b) injection for subcutaneous use; BUPHENYL (sodium phenylbutyrate) tablets and powder for oral use; QUINSAIR (levofloxacin) solution for inhalation; and UPLIZNA (inebilizumab-cdon) injection for intravenous use. The company also markets PENNSAID (diclofenac sodium topical solution) for topical use; DUEXIS (ibuprofen/famotidine) tablets for oral use; RAYOS (prednisone) delayed-release tablets for oral use; and VIMOVO (naproxen/esomeprazole magnesium) delayed-release tablets for oral use. It has collaboration agreements with Lupus Research and HemoShear Therapeutics, LLC. The company was formerly known as Horizon Pharma Public Limited Company and changed its name to Horizon Therapeutics Public Limited Company in May 2019. Horizon Therapeutics Public Limited Company was founded in 2005 and is headquartered in Dublin, Ireland with additional offices in Deerfield, Illinois; Chicago, Illinois; South San Francisco, California; Washington, D.C.; Gaithersburg, Maryland; Rockville, Maryland; and Mannheim, Germany.
Latest HOOK
- HOOKIPA Pharma Announces Completion of Sale of Oncology Assets to NeoTrail Therapeutics
- HOOKIPA Pharma Announces Sale of Oncology Assets to NeoTrail Therapeutics
- HOOKIPA Pharma Announces Completion of Sale of HBV and HIV Assets to Gilead
- Chief Executive Officer Peters Malte sold $20,684 worth of shares (25,172 units at $0.82), decreasing direct ownership by 32% to 54,347 units (SEC Form 4)
- SEC Form 15-12G filed by HOOKIPA Pharma Inc.
- SEC Form EFFECT filed by HOOKIPA Pharma Inc.
- SEC Form EFFECT filed by HOOKIPA Pharma Inc.
- SEC Form 25 filed by HOOKIPA Pharma Inc.
- SEC Form S-8 POS filed by HOOKIPA Pharma Inc.
- SEC Form S-8 POS filed by HOOKIPA Pharma Inc.
Latest HZNP
- Deep Track Capital Nominates Four Highly Qualified Candidates for Election to Dynavax Technologies' Board of Directors at 2025 Annual Meeting
- SEC Form 15-12G filed by Horizon Therapeutics Public Limited Company
- Watkins Thomas returned $20,550,600 worth of Ordinary Shares to the company (176,400 units at $116.50), closing all direct ownership in the company (SEC Form 4)
- Mahony Susan returned $2,172,842 worth of Ordinary Shares to the company (18,651 units at $116.50), closing all direct ownership in the company (SEC Form 4)
- Witz Pascale returned $5,353,292 worth of Ordinary Shares to the company (45,951 units at $116.50), closing all direct ownership in the company (SEC Form 4)
- Grey Michael G returned $11,346,168 worth of Ordinary Shares to the company (97,392 units at $116.50), closing all direct ownership in the company (SEC Form 4)
- Daniel William F returned $9,271,652 worth of Ordinary Shares to the company (79,585 units at $116.50), closing all direct ownership in the company (SEC Form 4)
- Himawan Jeff returned $10,371,762 worth of Ordinary Shares to the company (89,028 units at $116.50), closing all direct ownership in the company (SEC Form 4)
- Shannon James Samuel returned $6,616,501 worth of Ordinary Shares to the company (56,794 units at $116.50), closing all direct ownership in the company (SEC Form 4)
- Santini Gino returned $13,935,031 worth of Ordinary Shares to the company (119,614 units at $116.50), closing all direct ownership in the company (SEC Form 4)